4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
about
Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype SelectivityThe CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinomaA molecular mechanics approach to modeling protein-ligand interactions: relative binding affinities in congeneric series.RelA Ser276 phosphorylation-coupled Lys310 acetylation controls transcriptional elongation of inflammatory cytokines in respiratory syncytial virus infection.Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer.Cyclin Dependent Kinase 9 Inhibitors for Cancer TherapySystematic Determination of Human Cyclin Dependent Kinase (CDK)-9 Interactome Identifies Novel Functions in RNA Splicing Mediated by the DEAD Box (DDX)-5/17 RNA HelicasesAdenovirus L-E1A activates transcription through mediator complex-dependent recruitment of the super elongation complexCyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers.Cyclin-dependent kinase inhibitors: a survey of recent patent literature.Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Pyrazoles as potential anti-angiogenesis agents: a contemporary overview.Overview of CDK9 as a target in cancer research.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.Discovery of nitroaryl urea derivatives with antiproliferative properties.Coordinate activities of BRD4 and CDK9 in the transcriptional elongation complex are required for TGFβ-induced Nox4 expression and myofibroblast transdifferentiation.CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells.Structural Bioinformatics Approach of Cyclin-Dependent Kinases 1 and 3 Complexed with Inhibitors.A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.A cancer-derived mutation in the PSTAIRE helix of cyclin-dependent kinase 2 alters the stability of cyclin binding.Identification of novel inhibitors against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.Modification of Boc-Protected CAN508 via Acylation and Suzuki-Miyaura Coupling.Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.Synthesis of 4-substituted pyrazole-3,5-diamines via Suzuki-Miyaura coupling and iron-catalyzed reduction.Novel thiosemicarbazides induced apoptosis in human MCF-7 breast cancer cells via JNK signaling.Efficient and Convenient Route for the Synthesis of Some New Antipyrinyl Monoazo Dyes: Application to Polyester Fibers and Biological EvaluationFluorine Substituted 1,2,4-Triazinones as Potential Anti-HIV-1 and CDK2 Inhibitors
P2860
Q27675539-EF9F6986-32CA-4079-918F-AC62ACD63ADBQ27676963-E2D31977-C6E2-4FC0-8910-876F2F28F5DDQ31160552-C99AE252-2890-4E37-A310-1003D7378D56Q33709855-922C7537-9CE9-4FA5-9AFE-6405B86B3849Q35243650-F903D65F-5999-4433-853A-A31F43FEE7BFQ35531231-9471B735-36AB-4BEB-8330-25C4EF89BE72Q35903324-AE01CB51-78FB-4FA9-879C-BEAC3D7E5EF1Q36015334-51CE1683-C046-4BA4-A6FE-884D60AD0EB5Q36133996-60A3DE3F-328D-4768-8D6E-CA8F85DCF9E7Q36667837-59F5D5D4-EEE7-47CF-8B8F-D791342E6314Q37536656-128C25F3-EB5E-486B-896E-849F4C719810Q37697797-500A5FE3-DB85-4B48-A6A8-FB3D0BB01613Q37855864-9495EAED-DB76-4180-B583-7D9C1EB2DA2DQ38008733-6682D444-BD31-445C-8798-6F194097386AQ38253652-E90DC443-4E73-4359-A91D-0CF62904B48AQ38696353-70D5002E-AFBA-4790-A21C-2E4BFE7D0CA6Q38806786-8D08E25A-B7BD-4090-A16E-BAE297F8CD01Q38859827-6B5B404C-9133-4D6F-8C98-DDDAA6CE0FEEQ38970003-91EF0964-7C5F-422E-A7C9-660FE45444B4Q39164217-752506CE-31E9-4A13-BB36-9905D8F927DFQ39551472-868D29D6-8063-4605-856D-705AA8040D60Q39679283-86EB2F78-9DDA-4641-97A6-121EDDCC5BABQ39713734-8D2B2880-99FA-4EA1-9B69-A4C1FF5D6C02Q41457054-30B7E153-FF6E-4FAD-BCFB-8D753B0F9E05Q47787864-DE58CA1E-6887-4455-B0AD-D3CADC09A80FQ48253446-005AA108-720A-4D3E-8317-89AD03E93585Q49536215-F4EEB7D3-1C32-4E89-943D-D0D4C1080136Q49611613-305F507B-7448-4A5D-A5B8-6BDE12BD4C92Q55070378-E2F8FDE2-E27D-453E-A2A3-3276AD7C23DAQ59011499-AA4A3198-920F-45C1-A550-6739335E07CFQ59055934-2E7E4DD4-BA2E-41EE-8AAF-C1B8584EC768
P2860
4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
4-arylazo-3,5-diamino-1H-pyraz ...... ctivity, and cellular effects.
@en
type
label
4-arylazo-3,5-diamino-1H-pyraz ...... ctivity, and cellular effects.
@en
prefLabel
4-arylazo-3,5-diamino-1H-pyraz ...... ctivity, and cellular effects.
@en
P2093
P50
P356
P1476
4-arylazo-3,5-diamino-1H-pyraz ...... ctivity, and cellular effects.
@en
P2093
George Kontopidis
Iveta Frysová
Jakub Rolcík
Jan Slouka
Josef Srovnal
Marián Hajdúch
Martin Orság
Martina Paprskárová
Petr Cankar
P304
P356
10.1021/JM0605740
P407
P577
2006-11-01T00:00:00Z